Boundless Bio Q3 2026 Results: Net Loss of $5.36M, Loss Narrows
Boundless Bio, Inc. has entered into a definitive merger agreement with Serapha Bio, Inc., which will result in significant ownership dilution for existing stockholders and a potential reverse stock split. The company remains a clinical-stage biopharmaceutical firm with no revenue, a limited operating history, and expectations of continued significant operating losses as it develops its extrachromosomal DNA (ecDNA) directed therapeutic candidates.
- Key figure
- Net loss $5.36M